eWEEK content material and product suggestions are editorially unbiased. We might generate profits whenever you click on on hyperlinks to our companions. Learn More.
AI drug design and improvement firm Isomorphic Labs introduced on Monday that it raised $600 million in its first exterior funding spherical.
Thrive Capital led the financing spherical with participation from Google’s GV, and follow-on capital from Alphabet, its mother or father firm and an current investor. Isomorphic Labs described plans to make use of the funds to drive biomedical advances by its AI drug design engine. The firm can also be enhancing its drug design applications to span a broader vary of drug modalities and therapeutic areas.
Founded by Alphabet, constructing on DeepMind breakthroughs
Since its founding in 2021 by Alphabet, Isomorphic Labs has been no stranger to the AI biotech panorama. The AI analysis lab has developed a number of next-generation AI fashions that may be mixed to kind a unified AI drug design engine, and obtained a Nobel Prize for the event of AlphaFold, an AI platform that predicts protein constructions. This new funding will assist Isomorphic Labs’ mission to advance its AI drug design engine and fund its increasing crew of expertise as the corporate grows.
CEO Hassabis: “Funding will turbocharge AI drug design mission”
In an announcement Isomorphic Labs founder and CEO, Sir Demis Hassabis, stated “This funding will additional turbocharge the event of our next-generation AI drug design engine, assist us advance our personal applications into medical improvement, and is a major step ahead in the direction of our mission of someday fixing all illness with the assistance of AI.ˮ
Since its founding, Isomorphic Labs has seen a number of developments in AI fashions. Its AlphaFord three mannequin, launched in May 2024 by Isomorphic Labs and Google DeepMind, is able to precisely predicting the construction and interactions of molecules. Breakthroughs like this convey the corporate additional in its mission to quickly develop and improve AI drug design engines relevant throughout a number of therapeutic areas and drug modalities.
Investors’ curiosity in healthcare AI is excessive
As exemplified by this funding spherical, investor curiosity stays excessive for healthcare AI initiatives. The international market for AI in drug discovery is primed for progress, having been at $1.99 billion in 2024 and is estimated at $2.65 billion in 2025. The market measurement is predicted to proceed increasing over the last decade at a CAGR of 29.6% from 2025 to 2034, when it’s predicted to achieve round $35.42 billion.
